A cohort study using ctDNA for HER2-positive breast cancer with sustained therapeutic effects from anti-HER2 treatment

Personalized Detection of ctDNA for Patients with HER2 Positive Metastatic Breast Cancer who Achieved Durable Response by Anti-HER2 Treatment - HER2CR

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055735

Enrollment

Registered

2024-10-03

Start date

2024-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive metastatic breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Histologically invasive breast cancer. Diagnosed with unresectable HER2-positive breast cancer Drug therapy, including anti-HER2 therapy, was initiated between January 1, 2000, and December 31, 2021. Maintained partial or complete response for more than two years with drug therapy, including anti-HER2 therapy. Women aged 20 years or older.

Exclusion criteria

Exclusion criteria: Patients deemed unsuitable as research subjects by the physicians' judgment, such as those possibly receiving inappropriate treatment.

Design outcomes

Primary

Measure	Time frame
The positivity rate of ctDNA	—

Secondary

Measure	Time frame
Association between ctDNA status and treatment response Comparison between ctDNA-negative and ctDNA-positive groups	—

Countries

Japan

Contacts

Public ContactKazuki Nozawa

Nagoya City University Department of Advanced Clinical Research and Development

kazuki.nozawa7@gmail.com0528538628

Outcome results